A stem cell therapy for dog arthritis just cleared a major FDA hurdle

Doges Editorial · 2026-05-08 · 8 min read

A stem cell therapy for dog arthritis just cleared a major FDA hurdle

On May 6, biotech company Gallant announced that its IV-delivered stem cell treatment for canine osteoarthritis has expanded FDA conditional approval eligibility — and pilot data from 88 dogs shows significant improvement by day 60.

More than 80 percent of dogs over the age of eight have some degree of osteoarthritis. Most of their owners don't know it — because dogs are extraordinarily good at hiding pain. They slow down gradually. They take longer to get up. They stop asking for the long walks they once demanded. Their owners often interpret this as aging rather than suffering, because the two look very similar from the outside, and because dogs have evolved over millennia to mask weakness.

On May 6, 2026, Gallant, a veterinary biotech company, announced that its IV-delivered stem cell therapy for canine osteoarthritis has received expanded eligibility under the FDA's conditional approval pathway — and released pilot data from 88 client-owned dogs showing significant clinical improvement at both the 60- and 90-day marks post-treatment.

The scale of the problem

Osteoarthritis is the most common chronic condition in dogs. The statistics accumulate steeply with age: OA affects more than 20 percent of dogs over one year old, more than 40 percent of dogs over four, and up to 80 percent of dogs over eight. Despite its prevalence, treatment options for canine OA have historically been limited primarily to pain management — NSAIDs, joint supplements, physical therapy — rather than anything that addresses the underlying disease process.

The disease is progressive. Cartilage, once degraded, does not regenerate. Current standard-of-care treatments can meaningfully improve quality of life, but they work with the disease rather than against it. The gap between what is available and what is needed — a treatment that could actually slow or modify the degenerative process — has been the central challenge of canine OA research for decades.

A new approach to an old problem

Gallant's approach uses umbilical mesenchymal stem cells (UMSCs) — stem cells derived from umbilical cord tissue, with anti-inflammatory and immunomodulatory properties that have been studied in both human and veterinary medicine. The therapy targets what researchers describe as the systemic and local immune dysregulation that precedes and drives the degenerative changes of OA, rather than simply managing the pain those changes produce.

By targeting the systemic and local immune dysregulation that precedes the progressive, degenerative changes of OA, MSC therapy has the potential to not only control clinical signs but also impact the course of disease.

— Dr. Rebecca Windsor, DVM, DACVIM, VP of Veterinary Affairs, Gallant

The distinction Dr. Windsor draws — between controlling symptoms and impacting the course of disease — is the central promise of the therapy. Anti-inflammatory drugs reduce pain and improve mobility. Stem cell therapy, if the mechanism holds, may do both of those things while also addressing what's actually happening in the joint. That would represent a qualitatively different treatment than anything currently in widespread veterinary use.

The pilot study

The pilot trial enrolled 88 client-owned dogs with radiographically confirmed osteoarthritis — meaning dogs whose OA was verified by X-ray, not just by clinical presentation. Participants were randomized to receive either the UMSC therapy or saline (the control). Treatment consisted of two intravenous injections, administered 14 days apart. The dogs were then assessed at Day 60 and Day 90.

The treated group showed significant improvement at both timepoints compared to the control group. No treatment-related serious adverse events were reported — an important safety finding, given that establishing a clean safety profile is a prerequisite for the regulatory pathway ahead. Gallant has not yet published the full trial data, but the press release describes the results as "promising" and characterizes them as sufficient to support continued advancement toward conditional approval.

IV delivery changes everything about access

One of the more significant details in Gallant's announcement is the delivery method. The therapy is administered intravenously — not as a direct joint injection, which requires specialized equipment and a veterinary specialist. An IV infusion can be administered by any licensed veterinarian, in any clinic, without specialized surgical training or equipment.

This matters enormously for access. Treatments that require specialist administration tend to cluster in urban academic veterinary centers, limiting availability for dogs in rural areas or with owners who can't afford the additional costs of specialist referral. If Gallant's therapy reaches the market in its current form, it could in theory be administered at any veterinary practice — making regenerative medicine for OA accessible to a much larger portion of the approximately 90 million dogs in the United States.

The FDA conditional approval pathway

The FDA's conditional approval pathway for animal drugs is designed to accelerate access to treatments for serious conditions when there is a reasonable expectation of effectiveness and a demonstrated safety profile, even before full effectiveness data is available. Gallant's expanded eligibility under this pathway means the company can continue accumulating effectiveness data while working toward a conditional approval that would allow commercial use of the therapy.

The company is targeting conditional approval for 2028 — roughly two years from the current pilot data announcement. That timeline will require continued clinical work, additional regulatory submissions, and the kind of manufacturing scale-up that precedes any commercial veterinary product launch. Two years is not fast; it's also not slow, for a novel biologic therapy moving through a demanding regulatory process.

This is another positive step toward revolutionizing how we treat OA in dogs. We're encouraged by the pilot data, and it moves us closer to making regenerative medicine a real and practical option for all veterinarians treating dogs suffering from OA.

— Dr. Linda Black, DVM, PhD, CEO, Gallant

What to watch for in your dog

Given how effectively dogs mask pain, the behavioral signs of OA are worth knowing and watching for. Reluctance to jump — onto furniture, into cars, up stairs — is often among the first visible indicators. So is stiffness after rest, particularly in the morning or after a long nap: the dog who takes several steps before her gait normalizes. Reduced interest in play, shortened walk tolerance, or lagging on routes she used to set the pace on.

These signs are easy to attribute to general aging, which is why OA is so frequently underdiagnosed. Any dog over six or seven who shows behavioral changes worth noticing is a candidate for a veterinary assessment that includes OA screening — particularly if she belongs to a large breed, has a history of orthopedic injury, or carries extra weight. The X-ray that confirms OA is the starting point for whatever comes next.

The bigger picture

Gallant's announcement lands in the context of a broader shift in veterinary medicine toward regenerative and biologic therapies — an approach borrowed, with appropriate adaptation, from human medicine, where stem cell research has been advancing for decades. The pipeline for canine regenerative medicine includes treatments for cancer, heart disease, and neurological conditions in addition to orthopedic applications.

Gallant's existing business already intersects with the stem cell space through its cord blood banking service — a product that allows dog owners to preserve their puppy's stem cells at birth for potential future use. The OA therapy announced this week is a separate product using donor umbilical cells rather than the individual dog's banked material, but the underlying scientific platform is related. The company has been building toward clinical applications of canine stem cell science for years; the FDA pathway eligibility is the most significant regulatory milestone that work has reached.

For the millions of dog owners watching their animals slow down on walks, stop taking stairs, wake up stiff — the prospect of a treatment that might actually change the course of that decline rather than simply managing it is meaningful. Dogs don't tell us how much they hurt. They just ask us to pay attention. The research community is paying attention. That milestone is the most tangible evidence yet that the science is moving in the right direction. The dogs suffering from osteoarthritis right now deserve that urgency, and their owners deserve a real option beyond pain management alone.